Established in June 2021 in Shanghai, China. Brise Pharma stands as a clinical stage biopharmaceutical company with a major focus on the development of innovative and highly differentiated treatment solutions for severe pain conditions, especially for addressing issues such as migraine, inflammatory pain, and neuropathic pain.
Brise Pharma was originally formed by a group of veterans with an average of over 15 years extensive experience in drug R&D with global perspective, ranging from preclinical study, clinical development to financing, investment and company operations.